Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. has submitted a rolling submission to the U.S. Food and Drug Administration (FDA) for Xocova as a prevention measure against COVID-19.

Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. submitted an application in Japan for an additional indication of new coronavirus treatment Xocova for the prevention of COVID-19.

Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. received approval for a new drug application in Taiwan and signed a government stockpiling agreement

Collaboration with Shionogi for drug discovery – COVID-19 treatment drug “Xocova” effect on Long COVID

Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study

Collaboration with Shionogi for drug discovery – the first domestically produced COVID-19 treatment, Xocova was approved